A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: No pharmacologic therapy has conclusively proved to be effective for the treatment of nonalcoholic steatohepatitis, which is characterized by insulin resistance, steatosis, and necroinflammation with or without centrilobular fibrosis. Pioglitazone is a thiazolidinedione that ameliorates insulin resistance and improves glucose and lipid metabolism in type 2 diabetes mellitus. METHODS: We randomly assigned 55 patients with impaired glucose tolerance or type 2 diabetes and liver biopsy-confirmed nonalcoholic steatohepatitis to 6 months of treatment with a hypocaloric diet (a reduction of 500 kcal per day in relation to the calculated daily intake required to maintain body weight) plus pioglitazone (45 mg daily) or a hypocaloric diet plus placebo. Before and after treatment, we assessed hepatic histologic features, hepatic fat content by means of magnetic resonance spectroscopy, and glucose turnover during an oral glucose tolerance test ([14C]glucose given with the oral glucose load and [3H]glucose given by intravenous infusion). RESULTS: Diet plus pioglitazone, as compared with diet plus placebo, improved glycemic control and glucose tolerance (P<0.001), normalized liver aminotransferase levels as it decreased plasma aspartate aminotransferase levels (by 40% vs. 21%, P=0.04), decreased alanine aminotransferase levels (by 58% vs. 34%, P<0.001), decreased hepatic fat content (by 54% vs. 0%, P<0.001), and increased hepatic insulin sensitivity (by 48% vs. 14%, P=0.008). Administration of pioglitazone, as compared with placebo, was associated with improvement in histologic findings with regard to steatosis (P=0.003), ballooning necrosis (P=0.02), and inflammation (P=0.008). Subjects in the pioglitazone group had a greater reduction in necroinflammation (85% vs. 38%, P=0.001), but the reduction in fibrosis did not differ significantly from that in the placebo group (P=0.08). Fatigue and mild lower-extremity edema developed in one subject who received pioglitazone; no other adverse events were observed. CONCLUSIONS: In this proof-of-concept study, the administration of pioglitazone led to metabolic and histologic improvement in subjects with nonalcoholic steatohepatitis. Larger controlled trials of longer duration are warranted to assess the long-term clinical benefit of pioglitazone. (ClinicalTrials.gov number, NCT00227110 [ClinicalTrials.gov] .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Significant improvements were observed in hepatic steatosis, hepatocellular ballooning, necrosis, and inflammation; however, fibrosis reduction did not reach statistical significance compared with placebo.”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [202]
In the citing paper
“Accruing randomized clinical trial data suggest that pioglitazone, GLP-1 RA, and a dual GIP and GLP-1 RA have potential benefits in terms of decreasing hepatic steatosis and in the resolution of MASH without worsening of fibrosis in individuals with biopsy-proven MASH or those at higher risk of clinically significant liver fibrosis identified with noninvasive tests (146-153).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [146]
In the citing paper
“Treatment with exenatide reduced liver steatosis [109,146,150] and when added to pioglitazone, an oral hypoglycemic and insulin sensitizing drug approved for the treatment of T2D that acts on nuclear peroxisome proliferator activated receptor-gamma (PPAR-γ) [147], potentiated the known action of pioglitazone in reducing hepatic fat [92].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [92]
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Self-citationYamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., et al. (2002) · Nature Medicine · doi:10.1038/nm788 · Cited by 4,238
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease
Ratziu, V., Charlotte, F., Heurtier, A., Gombert, S., Giral, P., Bruckert, E., Grimaldi, A., Capron, F., & Poynard, T. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.084 · Cited by 2,106
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772
Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease
Samuel, V. T., Liu, Z.-X., Qu, X., Elder, B. D., Bilz, S., Befroy, D., Romanelli, A. J., & Shulman, G. I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313478200 · Cited by 1,322
Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317797 · Cited by 1,298
Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17797 · Cited by 1,296
Research works printed but not linked: 3
- 10.1111/j.1572-0241.2003.08699.x · doi:10.1111/j.1572-0241.2003.08699.x · Paper page
- 10.1210/jc.87.6.2784 · doi:10.1210/jc.87.6.2784 · Paper page
- 10.1172/JCI22422 · DOI · Paper page
Cited by
Items 601–700 of 1,003
A placebo-controlled trial of silymarin in patients with nonalcoholic fatty liver disease.
Hashemi, S. J., Hajiani, E., & Sardabi, E. H. (2009) · Cited by 63
Tang, W., Xu, Q., Hong, T., Tong, G., Feng, W., Shen, S., Bi, Y., & Zhu, D. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2713 · Cited by 63
Lonardo, A., Bellentani, S., Ratziu, V., & Loria, P. (2011) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.11.19 · Cited by 65
Vilar‐Gomez, E., Calzadilla‐Bertot, L., Friedman, S. L., Gra‐Oramas, B., Gonzalez‐Fabian, L., Lazo‐del Vallin, S., Diago, M., & Adams, L. A. (2017) · Liver International · doi:10.1111/liv.13480 · Cited by 63
NAFLD/NASH in patients with type 2 diabetes and related treatment options
Radaelli, M. G., Martucci, F., Perra, S., Accornero, S., Castoldi, G., Lattuada, G., Manzoni, G., & Perseghin, G. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0799-3 · Cited by 68
Visceral fat: A key mediator of NAFLD development and progression
Bansal, S., Vachher, M., Arora, T. K., Kumar, B., & Burman, A. (2023) · Human Nutrition & Metabolism · doi:10.1016/j.hnm.2023.200210 · Cited by 75
Schlegel, A. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1037-y · Cited by 67
Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: Clinical Implications and Treatment
Rahimi, R. S., & Landaverde, C. (2013) · Nutrition in Clinical Practice · doi:10.1177/0884533612470464 · Cited by 61
Phase 3 drug pipelines in the treatment of non‐alcoholic steatohepatitis
Sumida, Y., Okanoue, T., Nakajima, A., & Japan Study Group of NAFLD (JSG‐NAFLD) (2019) · Hepatology Research · doi:10.1111/hepr.13425 · Cited by 65
Current histological classification of NAFLD: strength and limitations
Bédossa, P. (2013) · Hepatology International · doi:10.1007/s12072-013-9446-z · Cited by 71
Scheen, A. J. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.902444 · Cited by 66
“In a proof-of-concept study, the administration of pioglitazone, acting as an insuli-sensitizer compound, led to metabolic and histologic improvement in subjects with NASH [64].”
BackgroundResultNonalcoholic Fatty Liver Disease: Pathogenesis, Identification, Progression, and Management
Yan, E., Durazo, F. A., Tong, M. J., & Hong, K. M. (2007) · Nutrition Reviews · doi:10.1111/j.1753-4887.2007.tb00315.x · Cited by 73
“Given the relationship between insulin resistance and NAFLD, an insulin sensitizer is preferred in those with diabetes and NAFLD.(67) It is also safe to use statins to treat hyperlipidemia with careful monitoring of their hepatic side-effect profile.”
BackgroundSawangjit, R., Chongmelaxme, B., Phisalprapa, P., Saokaew, S., Thakkinstian, A., Kowdley, K. V., & Chaiyakunapruk, N. (2016) · Medicine · doi:10.1097/md.0000000000004529 · Cited by 61
Shahmohammadi, H. A., Hosseini, S. A., Hajiani, E., Malehi, A. S., & Alipour, M. (2017) · Hepatitis Monthly · doi:10.5812/hepatmon.45609 · Cited by 61
“Several studies have shown that NAFLD patients have significantly higher serum levels of markers of oxidative stress and inflammation (43, 44).”
BackgroundThrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH)
Min-DeBartolo, J. H., Schlerman, F. J., Akare, S., Wang, J., McMahon, J. B., Zhan, Y., Syed, J., He, W., Zhang, B., & Martinez, R. V. P. (2019) · PLoS ONE · doi:10.1371/journal.pone.0226854 · Cited by 69
“Another PPARα and PPARγ agonist compound, pioglitazone, was found to improve NAFLD in diabetic and non-diabetic patients [46, 47].”
BackgroundShannon, C. E., Ragavan, M., Palavicini, J. P., Fourcaudot, M. J., Bakewell, T. M., Valdez, I., Ayala, I., Jin, E. S., Madesh, M., Han, X., et al. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101154 · Cited by 68
“In the first placebo-controlled human trial, pioglitazone treatment for 6 months reduced hepatic steatosis, hepatocyte ballooning, and inflammation [15].”
BackgroundRole of liver sinusoidal endothelial cell in metabolic dysfunction-associated fatty liver disease
He, Q., He, W., Dong, H., Guo, Y., Yuan, G., Shi, X., Wang, D., & Lu, F. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01720-9 · Cited by 73
“In addition, a meta-analysis of all available randomized trials showed that pioglitazone was beneficial in patients with advanced fibrosis [187–190].”
BackgroundMethodTsochatzis, E. A., Manolakopoulos, S., Papatheodoridis, G., & Archimandritis, A. J. (2008) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520802273058 · Cited by 63
“[4] Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al.”
BackgroundFernandes-Santos, C., Evangelista Carneiro, R., de Souza Mendonca, L., Barbosa Águila, M., & Alberto Mandarim-de-Lacerda, C. (2009) · Pancreas · doi:10.1097/mpa.0b013e3181987d9d · Cited by 60
Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease
Gatselis, N., Ntaios, G., Makaritsis, K. P., & Dalekos, G. Ν. (2013) · Clinical and Experimental Medicine · doi:10.1007/s10238-012-0227-0 · Cited by 70
PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells
Rogue, A., Anthérieu, S., Vluggens, A., Umbdenstock, T., Claude, N., de la Moureyre-Spire, C., Weaver, R. J., & Guillouzo, A. (2014) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2014.02.001 · Cited by 65
“, 2008) and pioglitazone (Belfort et al., 2006).”
Role of mitochondria and mitochondria‐targeted agents in non‐alcoholic fatty liver disease
Ajith, T. A. (2017) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12886 · Cited by 66
Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?
Budd, J., & Cusi, K. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.01.007 · Cited by 60
Self-citationPharmacological agents for NASH
Ratziu, V. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.193 · Cited by 64
Causes of and Prevention Strategies for Hepatocellular Carcinoma
Cabibbo, G., Maida, M. F., Genco, C., Antonucci, M., & Cammà, C. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.05.006 · Cited by 59
The Role of Nuclear Receptors in the Pathogenesis and Treatment of Non-alcoholic Fatty Liver Disease
Yang, Z., Danzeng, A., Liu, Q., Zeng, C., Xu, L., Mo, J., Ciren, P., Wang, X., Wang, C., Zhang, B., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.87305 · Cited by 67
“In phase Ⅱ b trials, pioglitazone notably improve liver histology liver histology features such as steatosis, inflammation, and ballooning, but not other histological features of NASH[7, 104, 105].”
BackgroundNoninvasive diagnosis of nonalcoholic fatty liver disease
Myers, R. P. (2009) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31823-x · Cited by 64
“Third, although there are currently no approved therapies for NAFLD, new treatments including insulin-sensitizing agents are under investigation in large-scale clinical trials.(7) Noninvasive markers that will facilitate identification of patients most in need of these treatments (i.”
BackgroundRazavizade, M., Jamali, R., Arj, A., Matini, S. M., Moraveji, A., & Taherkhani, E. (2013) · Hepatitis Monthly · doi:10.5812/hepatmon.9270 · Cited by 58
“A study on fiftyfive patients with NAFLD and impaired glucose tolerance or type two diabetes mellitus showed that pioglitazone (45 mg/day) was more effective than the placebo in reduction of serum ALT levels after six months (17).”
BackgroundResultInfluentialThiazolidinediones and the liver in humans
Yki-Järvinen, H. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283321d37 · Cited by 59
Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease
Budd, J. T., & Cusi, K. J. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01349-1 · Cited by 61
Self-citationNovel antidiabetic medications for non‐alcoholic fatty liver disease with type 2 diabetes mellitus
Sumida, Y., Seko, Y., Yoneda, M., & Japan Study Group of NAFLD (JSG‐NAFLD) (2017) · Hepatology Research · doi:10.1111/hepr.12856 · Cited by 60
Deletion of angiotensin II type I receptor reduces hepatic steatosis
Nabeshima, Y., Tazuma, S., Kanno, K., Hyogo, H., & Chayama, K. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.01.018 · Cited by 62
Krakoff, J. A., Clark, J. M., Crandall, J. P., Wilson, C., Molitch, M. E., Brancati, F. L., Edelstein, S. L., & Knowler, W. C. (2010) · Obesity · doi:10.1038/oby.2010.21 · Cited by 60
“That lowering of FI was not more effective in preventing abnormal ALT was surprising, as pioglitazone, an insulin sensitizer, decreases ALT and improves liver histology (7).”
BackgroundBobulescu, I. A., Dubree, M., Zhang, J., McLeroy, P., & Moe, O. W. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00177.2009 · Cited by 60
“These drugs have been shown to reduce skeletal muscle, heart, and liver steatosis in humans and animal models (4, 22, 38, 47, 52, 57), primarily by redistributing lipids to the adipose tissue (44, 55).”
BackgroundThe Association Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease Outcomes
Wong, C. R., & Lim, J. K. (2018) · Clinical Liver Disease · doi:10.1002/cld.721 · Cited by 64
Bea, S., Ko, H. Y., Bae, J. H., Cho, Y. M., Chang, Y., Ryu, S., Byrne, C. D., & Shin, J. (2024) · Gut · doi:10.1136/gutjnl-2024-332687 · Cited by 68
Hepatic steatosis and Type 2 diabetes: current and future treatment considerations
Richard, J., & Lingvay, I. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.15 · Cited by 57
Non‐alcoholic fatty liver disease
Tuyama, A. C., & Chang, C. (2012) · Journal of Diabetes · doi:10.1111/j.1753-0407.2012.00204.x · Cited by 69
Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease
Pelusi, S., & Valenti, L. (2019) · Liver International · doi:10.1111/liv.13972 · Cited by 57
Cho, K. Y., Nakamura, A., Omori, K., Takase, T., Miya, A., Yamamoto, K., Nomoto, H., Kameda, H., Taneda, S., Kurihara, Y., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13457 · Cited by 58
Cheon, S. Y., & Song, J. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00836-0 · Cited by 61
Tolman, K. G., Freston, J. W., Kupfer, S., & Pérez, A. (2009) · Drug Safety · doi:10.2165/11316510-000000000-00000 · Cited by 61
Effects of N-3 Fatty Acids on Hepatic Triglyceride Content in Humans
Vega, G. L., Chandalia, M., Szczepaniak, L. S., & Grundy, S. M. (2008) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e318177024d · Cited by 56
Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus
Portillo-Sanchez, P., & Cusi, K. (2016) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-016-0027-7 · Cited by 56
“[52], in a proof-of-concept 6-month trial in patients with prediabetes and T2DM, reported the first RCT of pioglitazone (plus a -500 kcal/day caloric restricted diet) in patients with biopsy-proven NASH.”
BackgroundSelf-citationPrecision medicine: The future in diabetes care?
Scheen, A. J. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.04.033 · Cited by 60
“efficacious to reduce hepatic fat content than others, especially thiazolidinediones (pioglitazone) [28] and GLP-1 receptor agonists (liraglutide) [29].”
BackgroundRafie, R., Hosseini, S. A., Hajiani, E., Malehi, A. S., & Mard, S. A. (2020) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s234698 · Cited by 63
Wang, C., Lin, S., Tseng, Y.-L., Hsu, C., Tseng, T., Lin, H. H., Wang, L., & Kao, J. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2009.05872.x · Cited by 57
Juurinen, L., Kotronen, A., Granér, M., & Yki‐Järvinen, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1825 · Cited by 58
Similarities and Differences in the Pathogenesis of Alcoholic and Nonalcoholic Steatohepatitis
Syn, W.-K., Teaberry, V., Choi, S., & Diehl, A. (2009) · Seminars in Liver Disease · doi:10.1055/s-0029-1214375 · Cited by 57
“Because specific TNFa antagonists are expensive and potentially toxic, and patients with NASH seldom, if ever, manifest the same florid features of hepatic decompensation that occur in patients with acute alcoholic hepatitis, specific TNFa antagonists have not been evaluated in humans with NASH.”
InfluentialThe Antifibrogenic Potential of PPARγ Ligands in Pulmonary Fibrosis
Sime, P. J. (2008) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e31816464e9 · Cited by 58
Vu, K., Gilbert, G., Chalut, M., Chagnon, M., Chartrand, G., & Tang, A. (2015) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.25083 · Cited by 59
Wang, S., Kamat, A., Pérgola, P. E., Swamy, A., Tio, F. O., & Cusi, K. J. (2011) · Metabolism · doi:10.1016/j.metabol.2010.12.001 · Cited by 58
“Inhumans,adipose tissue IRand increasedFFAdelivery to the liver are central in the development of lipotoxicity and steatohepatitis in obesity and T2DM [4,5,9,17].”
BackgroundInfluentialSelf-citationPediatric nonalcoholic fatty liver disease: Overview with emphasis on histology
Takahashi, Y., & Fukusato, T. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i42.5280 · Cited by 62
Thiazolidinediones for nonalcoholic steatohepatitis: A meta-analysis of randomized clinical trials
He, L., Liu, X., Wang, L., & Yang, Z. (2016) · Medicine · doi:10.1097/md.0000000000004947 · Cited by 55
“Increases in body fat were reported among the patients treated with TZDs in 3 of the RCTs.([23,24,28]) Significant heterogeneity”
BackgroundMethodResultInfluentialEffect of insulin–metformin combination on hepatic steatosis in patients with type 2 diabetes
Lingvay, I., Raskin, P., & Szczepaniak, L. S. (2007) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2007.02.005 · Cited by 55
“, 2004) after 3 months of therapy, and at 54% (Belfort et al., 2006) after 6 months of therapy.”
BackgroundResultBril, F., Barb, D., Lomonaco, R., Lai, J., & Cusi, K. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.09.018 · Cited by 55
Diabetes as a risk factor for MASH progression
Gancheva, S., Roden, M., & Castéra, L. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111846 · Cited by 65
Molecular Mechanisms of Hepatic Fibrosis in Non-Alcoholic Steatohepatitis
Rombouts, K., & Marra, F. (2010) · Digestive Diseases · doi:10.1159/000282094 · Cited by 54
“In patients with NASH, treatment with TZD has been shown to reduce fibrosis, although another study in Europe failed to confirm these results [ ,”
Galli, A., Ceni, E., Mello, T., Polvani, S., Tarocchi, M., Buccoliero, F., Lisi, F., Cioni, L., Ottanelli, B., Foresta, V., et al. (2010) · Hepatology · doi:10.1002/hep.23669 · Cited by 55
Ratziu, V., Bédossa, P., Francque, S., Larrey, D. G., Aithal, G. P., Serfaty, L., Voiculescu, M., Preoțescu, L., Nevens, F., de Lédinghen, V., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.01.040 · Cited by 56
Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis
Filipova, E. P., Uzunova, K. H., Kalinov, K., & Vekov, T. Y. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0290-5 · Cited by 54
“[14] examined pioglitazone’s effect over nonalcoholic steatohepatitis.”
BackgroundMethodRosselli, M. S., Burgueño, A. L., Carabelli, J., Schuman, M. L., Pirola, C. J., & Sookoian, S. C. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.01.026 · Cited by 57
Home, P. D., & Pacini, G. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00761.x · Cited by 54
Dhir, G., & Cusi, K. (2018) · Journal of Investigative Medicine · doi:10.1136/jim-2017-000554 · Cited by 53
Self-citationNonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment
Kim, K., Lee, B., Kim, Y. J., Lee, D. H., Soo, B., & Park, C. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0034 · Cited by 59
Wang, Z., Huiqing, D., Zhao, Y., Ren, Y., Ma, C., Chen, H., Li, M., Tian, J., Xue, C., Long, G., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1111430 · Cited by 73
Mucinski, J. M., Salvador, A. F., Moore, M. P., Fordham, T. M., Anderson, J. M., Shryack, G. E., Cunningham, R. P., Lastra, G., Gaballah, A. H., Diaz‐Arias, A. A., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.017 · Cited by 66
Gries, J. J., Lazarus, J. V., Brennan, P., Siddiqui, M. S., Targher, G., Lang, C. C., Virani, S. S., Lavie, C. J., Isaacs, S. D., Arab, J. P., et al. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00310-8 · Cited by 68
“RCTs with liver histology have also demonstrated the benefit of pioglitazone as an agent that can reverse MASH 127-131 .”
Self-citationPeroxisome proliferator-activated receptor gamma inhibits hepatic fibrosis in rats
Wang, Z., Xu, J.-P., Zheng, Y.-C., Chen, W., Sun, Y.-W., Wu, Z.-Y., & Luo, M. (2011) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(11)60009-x · Cited by 59
Dongiovanni, P., Rametta, R., Fracanzani, A. L., Benedan, L., Borroni, V. N., Maggioni, P., Maggioni, M., Fargion, S. R., & Valenti, L. V. C. (2010) · BMC Gastroenterology · doi:10.1186/1471-230x-10-102 · Cited by 56
“As pharmacological modulation of PPARg showed promising results on steatosis and necroinflammation in most, but not all, patients with NAFLD, whereas the effect on fibrosis is still undefined [30,34], we hypothesized that functional genetic variants may influence disease progression.”
BackgroundThe safety of thiazolidinediones
Tolman, K. G. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.534982 · Cited by 53
“Ironically and paradoxically, TZDs are beneficial in the treatment of non-alcoholic fatty liver disease, albeit more so in patients who do not yet have diabetes [50-53].”
BackgroundEkstedt, M., Franzén, L. E., Mathiesen, U. L., & Kechagias, S. (2012) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2011.634024 · Cited by 53
“state that the NAS is not intended to replace the pathologist’s diagnostic determination of steatohepatitis [8] the NAS is frequently being used to define NASH in studies of NAFLD [17,18] as well as in treatment trials [19,20].”
MethodMetabolic syndrome and its association with nonalcoholic steatohepatitis
Bril, F., Sanyal, A., & Cusi, K. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.002 · Cited by 52
Self-citationMaldonado-Rojas, A. D. C., Zuarth-Vázquez, J. M., Uribe, M., & Barbero-Becerra, V. J. (2023) · Annals of Hepatology · doi:10.1016/j.aohep.2023.101182 · Cited by 60
MASLD/MASH and type 2 diabetes: Two sides of the same coin? From single PPAR to pan-PPAR agonists
Cooreman, M. P., Vonghia, L., & Francque, S. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111688 · Cited by 59
Okazaki, I., Noro, T., Tsutsui, N., Yamanouchi, E., Kuroda, H., Nakano, M., Yokomori, H., & Inagaki, Y. (2014) · Cancers · doi:10.3390/cancers6031220 · Cited by 61
“[101] showed no decrease in NASH fibrosis, but some decrease in inflammation in liver.”
BackgroundEvolving aspects of liver transplantation for nonalcoholic steatohepatitis
Charlton, M. (2013) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e3283615d30 · Cited by 53
“com a thiazolidinedione (pioglitazone) [44].”
Aoyama, T., Ikejima, K., Kon, K., Okumura, K., Arai, K., & Watanabe, S. (2009) · Hepatology · doi:10.1002/hep.22828 · Cited by 52
Role of nuclear receptor corepressor RIP140 in metabolic syndrome
Rosell, M., Jones, M. C., & Parker, M. G. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.12.016 · Cited by 56
Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review
Cazzo, E., Pareja, J. C., & Chaim, É. A. (2017) · Sao Paulo Medical Journal · doi:10.1590/1516-3180.2016.0306311216 · Cited by 60
Effect of pioglitazone on plasma ceramides in adults with metabolic syndrome
Warshauer, J. T., Lopez, X., Gordillo, R., Hicks, J., Holland, W. L., Anuwe, E., Blankfard, M. B., Scherer, P. E., & Lingvay, I. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2662 · Cited by 51
“which one would expect given pioglitazone’s ability to reduce liver fat and treat non-alcoholic steatohepatitis via a reduction of insulin resistance [21,39].”
BackgroundIron overload in nonalcoholic steatohepatitis
Fujita, N., & Takei, Y. (2011) · Advances in clinical chemistry · doi:10.1016/b978-0-12-387042-1.00006-x · Cited by 52
Role of thiazolidinediones, insulin sensitizers, in non‐alcoholic fatty liver disease
Chang, E., Park, C., & Park, S. W. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12107 · Cited by 51
“Pioglitazone 18 12 ; ; ; ; Belfort et al.(64) Pioglitazone 55 6 ; ; ; NS Lutchman et al.”
Bouhlel, M. A., Staels, B., & Chinetti‐Gbaguidi, G. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01892.x · Cited by 51
Jordy, A. B., Kraakman, M. J., Gardner, T., Estevez, E., Kammoun, H. L., Weir, J. M., Kiens, B., Meikle, P. J., Febbraio, M. A., & Henstridge, D. C. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00547.2014 · Cited by 51
A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
Makar, G. A. (2007) · Yearbook of Gastroenterology · doi:10.1016/s0739-5930(08)70229-0 · Cited by 51
Banini, B. A., & Sanyal, A. J. (2016) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s18885 · Cited by 61
NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs
Caldwell, S. H. (2017) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2017.0103 · Cited by 56
“Randomized and controlled trials, including the more recent PIVENS trial noted above, have consistently shown histological benefit with these agents in a sizable minority of treated patients (40-50% with histological response).(21,29,30) Similar results have been seen with rosiglitazone although subsequent concerns re…”
ResultMetabolic Effects of Betaine: A Randomized Clinical Trial of Betaine Supplementation in Prediabetes
Stanton, A. M., Patti, M., Lin, A. P., Beckman, J. A., Sahni, V. A., Cloutier, E., Fowler, K. M., Dreyfuss, J. M., Pan, H., Kozuka, C., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00507 · Cited by 57
Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?
Tacelli, M., Celsa, C., Magro, B., Giannetti, A., Pennisi, G., Spatola, F., & Petta, S. (2018) · Pharmaceuticals · doi:10.3390/ph11040121 · Cited by 51
“It is showed that Pioglitazone and Rosiglitazone, determinate a significant histologically improvement in steatosis and lobular inflammation, but no significant improvement was showed in terms of liver fibrosis, except for the RCT of 2006 [47] on Pioglitazone (where the fibrosis scores improved in the pioglitazone gro…”
BackgroundCusi, K. (2020) · Liver International · doi:10.1111/liv.14350 · Cited by 51
Self-citationEffectiveness of the PPARγ agonist, GW570, in liver fibrosis
Yang, L., Stimpson, S. A., Chen, L., Harrington, W. W., & Rockey, D. C. (2010) · Inflammation Research · doi:10.1007/s00011-010-0226-0 · Cited by 57
The Multifaceted Associations of Hepatobiliary Disease and Diabetes
Bell, D. S. H., & Allbright, E. (2007) · Endocrine Practice · doi:10.4158/ep.13.3.300 · Cited by 54
Review article: emerging anti‐fibrotic therapies in the treatment of non‐alcoholic steatohepatitis
Noureddin, M., Anstee, Q. M., & Loomba, R. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13620 · Cited by 51
“Pioglitazone has been shown to reduce liver fat content and liver enzymes and improve histology.(109) However, as mentioned above, the PIVEN trial that compared treatment of vitamin E with pioglitazone and placebo showed that vitamin E therapy was associated with a higher rate”
ResultKasahara, N., Imi, Y., Amano, R., Shinohara, M., Okada, K., Hosokawa, Y., Imamori, M., Tomimoto, C., Kunisawa, J., Kishino, S., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-46404-5 · Cited by 55
Liver Histology Changes in Nonalcoholic Steatohepatitis after One Year of Treatment with Probucol
Merat, S., Aduli, M., Kazemi, R., Sotoudeh, M., Sedighi, N., Sohrabi, M., & Malekzadeh, R. (2007) · Digestive Diseases and Sciences · doi:10.1007/s10620-007-0109-6 · Cited by 50
“, proglitazone combined with a low calorie diet was effective in reducing liver enzymes, necroinflammation, and steatosis [21].”
Dixon, A. E., Subramanian, M., DeSarno, M., Black, K. E., Lane, L., & Holguín, F. (2015) · Respiratory Research · doi:10.1186/s12931-015-0303-6 · Cited by 51
“In fact pioglitazone, at the doses used in the current trial, has significant efficacy in the treatment of nonalcoholic fatty liver disease, when compared with placebo [12, 36].”
BackgroundInfluentialNon-alcoholic fatty liver disease: What has changed in the treatment since the beginning?
Baran, B., & Akyüz, F. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i39.14219 · Cited by 59
Desmoplasia and chemoresistance in pancreatic cancer
Whatcott, C. J., Posner, R. G., Hoff, D. D. V., & Han, H. (2012) · Europe PMC (PubMed Central) · Cited by 78
Antifibrotics in chronic liver disease: tractable targets and translational challenges
Ramachandran, P., & Henderson, N. C. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30110-8 · Cited by 50
Metadata
- Authors
- Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., Berria, R., Ma, J. Z., Dwivedi, S., Havranek, R., Fincke, C., DeFronzo, R., Bannayan, G. A., Schenker, S., & Cusi, K.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Brooke Army Medical Center (US)
- South Texas Veterans Health Care System (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-11-30
- Volume
- 355
- Issue
- 22
- Pages
- 2297-2307
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2103156933
- Cited by
- 1,827
- References
- 38
- Citations by year
- 2026: 44 · 2025: 73 · 2024: 83 · 2023: 78 · 2022: 84 · 2021: 93 · 2020: 73 · 2019: 74 · 2018: 70 · 2017: 93 · 2016: 98 · 2015: 106 · 2014: 92 · 2013: 87 · 2012: 85
- FWCI
- 91.90
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Funders
- National Center for Research Resources (M01RR01346, M01RR001346)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- alcoholic steatohepatitis, thiazolidinediones, insulin resistance, hypocaloric diet, hepatic steatosis, hepatic insulin sensitivity, necroinflammation, liver fibrosis, glucose tolerance, type 2 diabetes, impaired glucose tolerance, hepatic aminotransferases, drug safety, adverse effects
- MeSH terms
- Pioglitazone, Blood Glucose, Combined Modality Therapy, Diabetes Mellitus, Type 2, Double-Blind Method, Fatty Liver, Female, Hepatitis, Humans, Hypoglycemic Agents, Insulin, Insulin Resistance, Liver, Liver Cirrhosis, Male, Middle Aged, Necrosis, Glucose Intolerance, Caloric Restriction, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.